Janssen Presents Longer-Term Talquetamab Follow-Up Data Show

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the...

Related Keywords

United States , Chicago , Illinois , American , Talquetamab Monotherapy , Satu Glawe , Bhagirathbhai Dholaria , Christie Corbett , Chris Heuck , Myeloma Center , Companies Of Johnson , Exchange Commission , Janssen Research Development , Oncology At Vanderbilt University Medical Center , Receptor Familyc Group , None Of The Janssen Pharmaceutical Companies , Division Of Hematology , European Commission , Johnson , Janssen Biotech Inc , National Comprehensive Cancer Network , American Society Of Clinical Oncology , American Society Of Hematology , University Of Arkansas , Janssen Pharmaceutical Companies Of Johnson , Eastern Cooperative Oncology Group , Janssen Pharmaceutical Companies , Clinical Oncology , Carolina Schinke , Associate Professor , Medical Sciences , Humoral Immunity , Refractory Multiple Myeloma Treated , Evaluating Talquetamab , Assistant Professor , Vanderbilt University Medical Center , Global Medical Head , Janssen Research , Part One , Orphan Drug Designation , Breakthrough Therapy Designation , Biologics License Application , Janssen Biotech , National Comprehensive Cancer , Interference With Serological , With Determination , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Janssen Pharmaceutical , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Refractory Multiple , Patients With , Refractory Multiple Myeloma , Oral Presentation , American Society , Natl Acad Sci United , Prescribing Information , Janssen Oncology ,